Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

EASL 2020 Virtual Conference: Rapid Audio Recap

August 27-29, 2020; Virtual
Hear insights from hepatology expert, Stefan Zeuzem, MD, on some of the most important new viral hepatitis data reported at the 2020 Digital International Liver Congress, organized by the European Association for the Study of the Liver. The studies highlighted in this podcast focus on HCV elimination and the treatment of HCV, HBV, and HDV infection.
Stefan Zeuzem, MD
Released: September 14, 2020

In this episode, Dr. Stefan Zeuzem discusses results from key viral hepatitis studies reported at the 2020 Digital International Liver Congress, organized by the European Association for the Study of the Liver, including important findings from the following reports:

  • Update on global progress toward HCV elimination goals
  • SToP-C: HCV treatment-as-prevention in Australian prisons
  • SHARED cohort: correlates of treatment failure with GLE/PIB or SOF/VEL/VOX
  • Trio Health: retreating HCV with GLE/PIB or SOF/VEL/VOX after DAA failure
  • Stop-NUC: discontinuation of long-term nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic HBV infection
  • High-dose bulevirtide for chronic HBV/HDV coinfection
  • Summary of select agents under early-phase investigation for HBV treatment

Content based on a CME program supported by an independent educational grant from Gilead Sciences.

Link to full program: https://www.clinicaloptions.com/hepatitis/conference-coverage/easl-2020/highlights

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Educational grant provided by
Gilead Sciences

Related Content

Watch this brief presentation by Dr. Grace Wong on determining treatment candidacy for patients with HBV infection

Grace LH Wong, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 5, 2021 Expired: March 4, 2022

Download free expert-authored slides reviewing APASL guidance on HBV pretreatment evaluation to determine treatment candidacy

Grace LH Wong, MD Released: March 5, 2021

Expert CCO commentary on how to incorporate noninvasive methods to assess fibrosis into management of patients with HBV infection

Paul Y. Kwo, MD Released: February 18, 2021

Watch this brief presentation by Dr. Paul Kwo on interpreting serology, HBV DNA, and fibrosis assessments to determine HBV treatment candidacy.

Paul Y. Kwo, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 16, 2021 Expired: February 15, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue